Most recently, an RCT investigating the effects of soluble recombinant thrombomodulin in patients with sepsis and SAC failed in 2019 because approximately 20% of the patients who had coagulopathy at the time of screening had experienced a spontaneous remission of SAC under standard sepsis therapy by the time the study drug was administered for the first time [14]. Here, THBD is linked to Sepsis.